Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Chromatics Color Sciences International. Inc; CCSI -- Ignore unavailable to you. Want to Upgrade?

To: Susan who wrote (725)	12/30/1997 8:37:00 PM
From: David S.	Respond to of 5736

Only a real dick would recommend CCSI. What I found interesting in the shareholder letter was the fact that management is finally fessing up regarding delays in marketing agreements, but in order to prop the stock up and keep you guys from getting pissed, they do a 3:2 stock split - well, that's a fair trade. Don't be pissed at me - I'm only the messenger.

To: Susan who wrote (725)	12/30/1997 9:10:00 PM
From: JanyBlueEyes	Read Replies (1) \| Respond to of 5736

Dick Davis Digest 12/29/97 *Special thanks to Karl Drobnik Volume 16, Issue 374 December 29, 1997 Quick Picks #4 Chromatics: The Science Of Color "Chromatics Color Sciences (CCSI 15 3/4 OTC) is developing Colormate, a technology that applies scientific color measurement to skin," says Karl Drobnic (Venture Returns, 1855 NW Tyler Ave., Corvallis, OR 97330, 24 issues, $75, 12/2/97). "A target market for Colormate is the detection and monitoring of certain diseases, including bilirubin infant jaundice. Chromatics' global market for this one disease is estimated at $1 billion _ if it makes the right distribution deal with a major medical device sales company. FDA clearance for bilirubin infant jaundice use has been obtained. Bilirubin is a liver disease that occurs shortly after birth. It affects almost all premature babies, and about half the rest. Every U.S. baby is tested for it. Non-invasive tests that don't involve blood draws have major safety advantages. The bilirubin test is the first of several 'killer apps' that could make Chromatic's patents dominant in color science. Other major diseases for which Chromatics may develop detection technology are anemia, hepatitus and TB. In addition to medical uses, the firm's technology can be used in such areas as quality control in manufacturing, cosmetics, dentistry, and even color coordination in consumer products. Chromatics shares should be in the $25-30 range by mid-1998, and much higher in 1999. Chromatics is a high risk/high reward speculative buy.**"